Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
About this study
This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.
- Condition
- Locally Advanced Melanoma
- Tested
- Fianlimab + Cemiplimab, Relatlimab + Nivolumab
- Sponsor
- John Kirkwood
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not stated
Inclusion 8
- Minimum age: 18 years
- Study condition: Locally Advanced Melanoma
- Study participants who meet inclusion criteria for the HCC 24-056 study will be eligible for this study.
- Participants must be willing to provide additional samples beyond what is required of them in HCC 24-056. These include:
- 3 additional tumor biopsies
- 3 additional blood draws
- Participants must have biopsiable non-target disease amenable to at least 3 biopsies.
- Must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion 1
- \. Study participants who do not qualify to enroll in the HCC 24-056 study will not be eligible for this study.
Where
1 site, 1 recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Contact
-
Danielle L Bednarz, RN
4126231191 bednarzdl@upmc.edu
-
Amy Rose, RN
4126478587 kennaj@upmc.edu
Potential match only. Final eligibility is determined by the study team.